Development of a predictive model for treatment decision making in older people with cancer

PROTEGER: PROgrama de Tamizaje y Evaluación oncoGERiátrica (Oncology Screening and Evaluation Program)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11875539

Enrollment

412

Registered

2024-08-28

Start date

2024-06-01

Completion date

Unknown

Last updated

2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Older people with oncological pathology (solid tumor) Cancer

Interventions

Current interventions as of 08/10/2025: Data from older people with oncological pathology will be used. All of them have received a comprehensive geriatric assessment at their respective centres and a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. People 65 years or older 2. Diagnosis of oncological pathology of solid tumours 3. The clinical case is presented to a local oncology committee or local oncology team 4. Patients in whom a CGA is performed

Exclusion criteria

Exclusion criteria: Patients who do not have the capacity or do not wish to consent to the delivery of information

Design outcomes

Primary

Measure	Time frame
The Machine Learning model performance will be evaluated with the Area Under Receiver Operating Characteristic Curve (AUC) compared to the decision of the Oncogeriatric team (no treatment, adjusted treatment, standard treatment).	—

Secondary

Measure	Time frame
3 and 6 months of follow up after the decision of the oncogeriatrics committee: 1. Longitudinal analysis of the patient quality of life measured using EORTC-QLQ-C30 2. Consultations to the Emergency Department and Hospitalisations measured using patient records 3. Adverse drug reaction measured using patient records 4. Treatment withdrawal measured using patient records 5. Chemotherapy dose delay or dose reduction measured using patient records 6. Functionality (Basics and Instrumental activity daily living measured with the Barthel Index and the Pfeffer test). 7. The ECOG Performance Status Scale. 8. Cognitive impairment measure The Telephone Screening of Cognitive Status (TICS), IQCODE 9. Overall survival and progression-free survival analysed by Kaplan–Meier survival and measured from patient records	—

Measure

Time frame

3 and 6 months of follow up after the decision of the oncogeriatrics committee: 1. Longitudinal analysis of the patient quality of life measured using EORTC-QLQ-C30 2. Consultations to the Emergency Department and Hospitalisations measured using patient records 3. Adverse drug reaction measured using patient records 4. Treatment withdrawal measured using patient records 5. Chemotherapy dose delay or dose reduction measured using patient records 6. Functionality (Basics and Instrumental activity daily living measured with the Barthel Index and the Pfeffer test). 7. The ECOG Performance Status Scale. 8. Cognitive impairment measure The Telephone Screening of Cognitive Status (TICS), IQCODE 9. Overall survival and progression-free survival analysed by Kaplan–Meier survival and measured from patient records

—

Countries

Chile

Contacts

Public ContactGonzalo Navarrete

gnavarrete@hcuch.cl+56 984798043

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026